Travaux scientifiques

Doç. Dr. Özlem Nuray Sever

81 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study

    Clinical Medicine Insights Oncology, 2026

    DOI 10.1177/11795549261445290 PMID 42131419 Texte intégral en libre accèsSource : OpenAlex

  2. Prevalence and Reactivation of Hepatitis B and C in Patients Undergoing Chemotherapy for Solid Tumors

    JCO Global Oncology, 2026

    DOI 10.1200/go-25-00234 PMID 41855443 Texte intégral en libre accèsSource : OpenAlex

  3. Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study

    Cancers, 2026

    DOI 10.3390/cancers18132127 PMID 42449669 Texte intégral en libre accèsSource : OpenAlex

  4. Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16664-1 Texte intégral en libre accèsSource : OpenAlex

  5. Prognostic role of smoking in metastatic renal cell carcinoma in real-world data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-35435-3 PMID 41548007 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  6. Prognostic Value of the Cancer Inflammation Prognostic Index (CIPI) in De Novo Metastatic Colon Cancer: A Multicenter Retrospective Cohort Study

    Cancer Control, 2026

    DOI 10.1177/10732748261432273 PMID 41779425 Texte intégral en libre accèsSource : ORCID

  7. Optimizing Antiemetic Strategies Across Phases of Chemotherapy-Induced Nausea and Vomiting: Real-World Evidence in Breast Cancer

    Current Oncology, 2026

    DOI 10.3390/curroncol33020078 PMID 41744842 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  8. Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14197103 PMID 41096183 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  9. The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-14252-3 PMID 40329228 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  10. Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium

    癌症：英文版, 2025

    DOI 10.1002/cac2.70003 PMID 39927571 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  11. The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer Consortium

    The Oncologist, 2025

    DOI 10.1093/oncolo/oyaf186 PMID 40577354 Texte intégral en libre accèsSource : OpenAlex

  12. Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study

    Immunotherapy, 2025

    DOI 10.1080/1750743x.2025.2527019 PMID 40611593 Texte intégral en libre accèsSource : OpenAlex

  13. Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study

    Medicina, 2025

    DOI 10.3390/medicina61010154 PMID 39859134 2 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  14. Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

    Clinical and Translational Oncology, 2025

    DOI 10.1007/s12094-024-03813-w PMID 39812937 6 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  15. Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-14654-3 PMID 40713516 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  16. Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium

    Therapeutic Advances in Medical Oncology, 2025

    DOI 10.1177/17588359251331540 PMID 40297625 Texte intégral en libre accèsSource : ORCID

  17. Efficacy of Palbociclib and Ribociclib in Second-line Treatment of Metastatic Hormone Receptor-positive Breast Cancer: A Single-center Experience

    Journal of Oncological Science, 2025

    DOI 10.37047/jos.galenos.2025.2025-4-2 Texte intégral en libre accèsSource : ORCID

  18. Relationship of Tumor Localization and Lipid Parameters with Survival in Patients with Colorectal Cancer

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14041302 PMID 40004832 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  19. Long-term Follow-up Results of Our Patients Diagnosed with Ductal Carcinoma In Situ: Usefulness of the Van Nuys Prognostic Index

    Journal of Oncological Sciences, 2025

    DOI 10.37047/jos.galenos.2025.2025-3-13 Texte intégral en libre accèsSource : OpenAlex

  20. The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-63096-7 PMID 38802494 21 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  21. Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis

    Medicina, 2024

    DOI 10.3390/medicina60081374 PMID 39202654 10 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  22. Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer: Impact of Tumor Ki67 and ER Status

    Chemotherapy, 2024

    DOI 10.1159/000537874 PMID 38368871 5 citations (Europe PMC) Source : OpenAlex

  23. A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients

    Cancers, 2024

    DOI 10.3390/cancers16142512 PMID 39061152 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  24. Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

    Journal of Clinical Medicine, 2024

    DOI 10.3390/jcm13206263 PMID 39458213 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  25. Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer?

    Medicina, 2024

    DOI 10.3390/medicina60081372 PMID 39202652 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  26. Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy

    Cureus, 2024

    DOI 10.7759/cureus.63362 PMID 39070363 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  27. Prognostic scores in pulmonary large cell neuroendocrine carcinoma: A retrospective cohort study

    Heliyon, 2024

    DOI 10.1016/j.heliyon.2024.e25029 PMID 38317875 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  28. Efficacy and Safety of Ixabepilone in Metastatic Breast Cancer After Multiple Treatments: Analysis Based on Real-World Data

    Journal of Oncological Sciences, 2024

    DOI 10.37047/jos.2024-102164 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  29. The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma

    Journal of Immunotherapy, 2024

    DOI 10.1097/cji.0000000000000508 PMID 38333962 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  30. Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

    Clinical Genitourinary Cancer, 2024

    DOI 10.1016/j.clgc.2024.102282 PMID 39709686 2 citations (Europe PMC) Source : OpenAlex

  31. Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

    2024

    DOI 10.20944/preprints202409.0812.v1 Texte intégral en libre accèsSource : ORCID

  32. The Predictive Value of Urinary HMGB1 Level in the Diagnosis and Prognosis of Renal Cell Carcinoma

    Eurasian Journal of Medical Advances, 2024

    DOI 10.14744/ejma.2024.93063 1 citation (OpenAlex) Texte intégral en libre accèsSource : ORCID

  33. The association of hemoglobin/red blood distribution width with overall survival: a retrospective analysis of melanoma

    Esperienze Dermatologiche, 2023

    DOI 10.23736/s1128-9155.23.00556-3 1 citation (OpenAlex) Source : OpenAlex

  34. 177Lu-PSMA-617 RLT in mCRPC: A single center experience, the earlier could be the better

    Revista Espanola de Medicina Nuclear E Imagen Molecular, 2023

    DOI 10.1016/j.remn.2021.11.004 Source : ORCID

  35. Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium

    Urologia Internationalis, 2023

    DOI 10.1159/000528994 PMID 36996793 3 citations (Europe PMC) Source : ORCID

  36. Onkolojide Güncel Tedavi Yaklaşımları 1

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1606 Source : OpenAlex

  37. Comparison of 68Ga-FAPI PET/CT and 18FDG PET/CT Modalities in Gastrointestinal System Malignancies with Peritoneal Involvement

    Molecular Imaging and Biology, 2022

    DOI 10.1007/s11307-022-01729-x PMID 35411447 35 citations (Europe PMC) Source : OpenAlex

  38. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

    Clinical Genitourinary Cancer, 2022

    DOI 10.1016/j.clgc.2022.07.006 PMID 35970759 6 citations (Europe PMC) Source : OpenAlex

  39. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-04055-5 PMID 35616728 22 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  40. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors

    Scientific Reports, 2022

    DOI 10.1038/s41598-022-20056-3 PMID 36192500 15 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  41. Gastrointestinal Sistem Tümörleri-2

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1212 Texte intégral en libre accèsSource : OpenAlex

  42. Role of serum cathelicidin in diagnosis of patient with prostatitis and prostate carcinoma

    African Journal of Urology, 2022

    DOI 10.1186/s12301-022-00330-6 Texte intégral en libre accèsSource : ORCID

  43. 177Lu-PSMA-617 RLT in mCRPC: A single center experience, the earlier could be the better

    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), 2022

    DOI 10.1016/j.remnie.2021.12.005 PMID 35193812 4 citations (OpenAlex) Source : OpenAlex

  44. Our Experience with Abiraterone and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer: Retrospective Real-Life Data

    Journal of Oncological Sciences, 2022

    DOI 10.37047/jos.2021-85879 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  45. The role of exosomal survivin in the diagnosis of breast cancer

    International Journal of Clinical Biochemistry and Research, 2022

    DOI 10.18231/j.ijcbr.2022.049 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  46. CLINICAL FACTORS PREDICTING RESPONSE TO REGORAFENIB IN METASTATIC COLORECTAL CANCER

    Euroasia Journal of Mathematics Engineering Natural and Medical Sciences, 2022

    DOI 10.38065/euroasiaorg.924 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  47. Survival Analysis of Our Patients Diagnosed with Testicular Cancer

    Eurasian Journal of Medical Investigation, 2022

    DOI 10.14744/ejmi.2022.66533 Source : OpenAlex

  48. Tumor Microenvironment and Mechanisms of Cancer Metastasis: An Overlooked Fact: Cell Fusion

    Journal of Oncological Sciences, 2022

    DOI 10.37047/jos.2022-89872 Texte intégral en libre accèsSource : OpenAlex

  49. Mide ve Kolorektal Kanser ile Serum Gama Glutamil Transferaz Düzeyleri Arasındaki İlişkinin İncelenmesi

    Acta Medica Nicomedia, 2022

    DOI 10.53446/actamednicomedia.1110063 Texte intégral en libre accèsSource : OpenAlex

  50. Efficacy and Tolerability of Current Treatments for Hormone-Refractory Prostate Cancer Patients with Visceral Metastases

    Future Oncology, 2021

    DOI 10.2217/fon-2020-1032 PMID 33631986 Source : OpenAlex